An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-Carboplatin or Second Line Tarceva (Erlotinib) on Progression-Free Survival in Non-Squamous Non-Small Cell Lung Cancer Patients With Asymptomatic Untreated Brain Metastasis.

Trial Profile

An Open Label Study to Assess the Effect of Avastin (Bevacizumab) Combined With First Line Paclitaxel-Carboplatin or Second Line Tarceva (Erlotinib) on Progression-Free Survival in Non-Squamous Non-Small Cell Lung Cancer Patients With Asymptomatic Untreated Brain Metastasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Erlotinib; Paclitaxel
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms BRAIN
  • Sponsors Roche
  • Most Recent Events

    • 15 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 15 Oct 2010 Planned end date changed from 1 Dec 2014 to 1 May 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top